HomeTechnologyTetratherix (ASX:TTX)

Tetratherix Launches $2M SPP Offering Shares at 2% Discount

Technology By Sophie Babbage 3 min read

Tetratherix Limited (ASX:TTX) has launched a $2 million share purchase plan offering eligible Australian and New Zealand shareholders the chance to buy shares at a 2% discount to recent trading prices. The non-underwritten SPP opens on 4 June and closes on 18 June 2026.

  • SPP offers up to $30,000 per eligible shareholder at $6 per share
  • Offer is non-underwritten with discretionary scale-back possible
  • Funds targeted for production expansion, partnerships, and digitalisation
  • Shares to rank equally with existing stock and commence trading 24 June
  • Participation limited to shareholders in Australia and New Zealand

SPP Launches to Raise $2 Million

Tetratherix Limited (ASX:TTX) has kicked off a share purchase plan (SPP) aiming to raise up to $2 million by inviting eligible shareholders in Australia and New Zealand to buy new shares at $6 each. This price represents a modest 2% discount to the volume-weighted average price (VWAP) over the ten trading days before the offer announcement on 28 May 2026.

The SPP opens on 4 June and closes on 18 June, with shares expected to be issued on 23 June and commence trading the following day. Eligible shareholders as of 7.00pm AEDT on 27 May 2026 can apply for up to $30,000 worth of shares without brokerage or transaction fees. The offer is non-underwritten, meaning the company may scale back applications at its discretion if demand exceeds the $2 million target.

Capital Raising Supports Growth Initiatives

The SPP forms part of a broader capital raising strategy, complementing a simultaneous institutional placement. Proceeds from both the placement and SPP will fund production expansion, strategic partnerships, customer success initiatives, digital transformation, working capital, and transaction costs. This capital injection aligns with Tetratherix’s ongoing efforts to scale manufacturing and commercial operations.

Participation is voluntary and limited to shareholders with registered addresses in Australia or New Zealand, excluding those acting for the benefit of US persons. Shares issued under the SPP will rank equally with existing shares, preserving shareholder rights and entitlements.

Application Process and Conditions

Eligible shareholders can apply by making a payment via BPAY® or electronic funds transfer (EFT) using a personalised reference number. The company warns that the market price of shares may fluctuate between the offer date and allotment, meaning investors could pay more or less than the prevailing market price at issue.

Applications exceeding $30,000 or those from ineligible shareholders will be rejected. If a scale-back occurs, applicants may receive fewer shares than requested, with any excess application money refunded without interest. The company also reserves the right to issue any shortfall to institutional investors.

Notably, the SPP offer is non-renounceable and non-transferable, preventing the trading or transfer of entitlements. The company advises shareholders to seek independent financial and taxation advice before participating.

Governance and Legal Framework

The SPP is governed by Australian law, specifically the Corporations Act and the ASX Listing Rules. The offer complies with ASIC’s relief instrument for share purchase plans, allowing the company to raise capital without a formal prospectus. Tetratherix has emphasised that the offer is not made to US persons and that shares will not be registered under US securities laws.

Investors should note that cooling-off rights do not apply, and applications are irrevocable once submitted. The company disclaims liability for any trading of SPP shares before holding statements are issued.

Bottom Line?

Tetratherix’s $2 million SPP offers a straightforward opportunity for eligible shareholders to increase their stake at a slight discount, supporting the company’s growth ambitions amid ongoing capital raising efforts.

Questions in the middle?

  • Will the SPP reach its $2 million target or trigger a scale-back?
  • How will the combined proceeds from the placement and SPP accelerate Tetratherix’s production expansion?
  • What impact might market price fluctuations have on shareholder participation and sentiment?